Hancock Jaffe Laboratories Inc ROCE
Quel est le ROCE de Hancock Jaffe Laboratories Inc?
Le ROCE de Hancock Jaffe Laboratories Inc est -27.53%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur NASDAQ par rapport à Hancock Jaffe Laboratories Inc
Que fait Hancock Jaffe Laboratories Inc?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Entreprises avec roce similaire à Hancock Jaffe Laboratories Inc
- Compass a ROCE de -27.67%
- Lineage Cell Therapeutics Inc a ROCE de -27.63%
- Kuya Silver a ROCE de -27.62%
- Pender Street Capital Corp a ROCE de -27.61%
- Buckhaven Capital a ROCE de -27.61%
- Seagen Inc a ROCE de -27.58%
- Hancock Jaffe Laboratories Inc a ROCE de -27.53%
- Y-Mabs Therapeutics Inc a ROCE de -27.49%
- Ramco Systems a ROCE de -27.47%
- Goldflare Exploration Inc a ROCE de -27.46%
- Gravitas One Capital a ROCE de -27.44%
- Arcturus Therapeutics Inc a ROCE de -27.43%
- Bellus Health Inc a ROCE de -27.42%